Zealand Pharma Financials
| ZEAL Stock | DKK 723.00 15.50 2.10% |
Zealand |
Understanding current and past Zealand Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Zealand Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Zealand Pharma's assets may result in an increase in income on the income statement.
Zealand Pharma Stock Summary
Zealand Pharma competes with Bavarian Nordic, Ambu AS, Genmab AS, ALK Abell, and FLSmidth. Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.| Foreign Associate | USA |
| Instrument | Denmark Stock View All |
| Exchange | Copenhagen Exchange |
| ISIN | DK0060257814 |
| Business Address | Sydmarken 11, Copenhagen, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.zealandpharma.com |
| Phone | 45 88 77 36 00 |
| Currency | DKK - Danish Krone |
You should never invest in Zealand Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Zealand Stock, because this is throwing your money away. Analyzing the key information contained in Zealand Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Zealand Pharma Key Financial Ratios
Zealand Pharma's financial ratios allow both analysts and investors to convert raw data from Zealand Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Zealand Pharma over time and compare it to other companies across industries.| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Target Price | 243.75 | |||
| Number Of Employees | 203 | |||
| Beta | 0.95 |
Zealand Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zealand Pharma's current stock value. Our valuation model uses many indicators to compare Zealand Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zealand Pharma competition to find correlations between indicators driving Zealand Pharma's intrinsic value. More Info.Zealand Pharma AS is rated fourth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Zealand Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zealand Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Zealand Pharma AS Systematic Risk
Zealand Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zealand Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Zealand Pharma AS correlated with the market. If Beta is less than 0 Zealand Pharma generally moves in the opposite direction as compared to the market. If Zealand Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zealand Pharma AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zealand Pharma is generally in the same direction as the market. If Beta > 1 Zealand Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Zealand Pharma November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Zealand Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zealand Pharma AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zealand Pharma AS based on widely used predictive technical indicators. In general, we focus on analyzing Zealand Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zealand Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 16.3 | |||
| Value At Risk | (5.08) | |||
| Potential Upside | 4.23 |
Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.